Modifying the osteoblastic niche with zoledronic acid in vivo-Potential implications for breast cancer bone metastasis

Bone

Volumn 66, Issue , 2014, Pages 240-250

  Haider, Marie Therese ^a   Holen, Ingunn ^a   Dear, T Neil ^b   Hunter, Keith ^a   Brown, Hannah K ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Breast cancer; Homing; Metastatic niche; Osteoblast; Osteoclast

Indexed keywords

BIOLOGICAL MARKER; TOLONIUM CHLORIDE; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; GREEN FLUORESCENT PROTEIN; IMIDAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CELL; BONE MASS; BONE METASTASIS; BONE TISSUE; BREAST CANCER; CANCER CELL; CARTILAGE; CELL HOMING; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; EXTRACELLULAR MATRIX; FEMALE; FLOW CYTOMETRY; GROWTH PLATE; IN VIVO STUDY; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; MULTIPHOTON MICROSCOPY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; SINGLE DRUG DOSE; SOFT TISSUE; TRABECULAR BONE; TUMOR CELL; ANIMAL; BAGG ALBINO MOUSE; BONE; BONE NEOPLASMS; BREAST TUMOR; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; HUMAN; IMMUNOCOMPROMIZED PATIENT; METABOLISM; NUDE MOUSE; ORGAN SIZE; PATHOLOGY; REPRODUCIBILITY; SECONDARY; TUMOR CELL LINE;

ANIMALS; BONE AND BONES; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; IMIDAZOLES; IMMUNOCOMPROMISED HOST; MICE, INBRED BALB C; MICE, NUDE; ORGAN SIZE; OSTEOBLASTS; OSTEOCLASTS; REPRODUCIBILITY OF RESULTS;

EID: 84904126701     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.06.023     Document Type: Article

References (40)

1. Lipton A., Theriault R.L., Hortobagyi G.N., Simeone J., Knight R.D., Mellars K., et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000, 88(5):1082-1090.
2. Coleman R.E. Should bisphosphonates be the treatment of choice for metastatic bone disease?. Semin Oncol 2001, 28(4 Suppl. 11):35-41.
3. Widler L., Jaeggi K.A., Glatt M., Muller K., Bachmann R., Bisping M., et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 2002, 45(17):3721-3738.
4. Riethmuller G., Klein C.A. Early cancer cell dissemination and late metastatic relapse: clinical reflections and biological approaches to the dormancy problem in patients. Semin Cancer Biol 2001, 11(4):307-311.
5. Guise T. Examining the metastatic niche: targeting the microenvironment. Semin Oncol 2010, 37(Suppl. 2):S2-S14.
6. Psaila B., Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009, 9(4):285-293.
7. Shiozawa Y., Havens A.M., Pienta K.J., Taichman R.S. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008, 22(5):941-950.
8. Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425(6960):841-846.
9. Shiozawa Y., Pedersen E.A., Havens A.M., Jung Y., Mishra A., Joseph J., et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 2011, 121(4):1298-1312.
10. Shiozawa Y., Pienta K.J., Taichman R.S. Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. Clin Cancer Res 2011, 17(17):5553-5558.
11. Brown H.K., Ottewell P.D., Evans C.A., Holen I. Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo. Clin Exp Metastasis 2012, 29(8):927-938.
12. Coleman R E H.S., Bell R., Camreon D., Dodwell D., Liversedge V., Burkinshaw R., Keane M., Gil M., Marshall H. Adjuvant therapy for stage II/III breast cancer with or without zoledronic acid. Final efficacy analysis of the AZURE trial 2013, Cancer and Bone Society, Miami, Florida.
13. Neudert M., Fischer C., Krempien B., Bauss F., Seibel M.J. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth. Int J Cancer 2003, 107(3):468-477.
14. van der Pluijm G., Que I., Sijmons B., Buijs J.T., Lowik C.W., Wetterwald A., et al. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res 2005, 65(17):7682-7690.
15. Garcia-Moreno C., Serrano S., Nacher M., Farre M., Diez A., Marinoso M.L., et al. Effect of alendronate on cultured normal human osteoblasts. Bone 1998, 22(3):233-239.
16. Greiner S., Kadow-Romacker A., Lubberstedt M., Schmidmaier G., Wildemann B. The effect of zoledronic acid incorporated in a poly(D, L-lactide) implant coating on osteoblasts in vitro. J Biomed Mater Res A 2007, 80(4):769-775.
17. Idris A.I., Rojas J., Greig I.R., Van't Hof R.J., Ralston S.H. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 2008, 82(3):191-201.
18. Orriss I.R., Key M.L., Colston K.W., Arnett T.R. Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem 2009, 106(1):109-118.
19. Corrado A., Neve A., Maruotti N., Gaudio A., Marucci A., Cantatore F.P. Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures. Clin Exp Rheumatol 2010, 28(6):873-879.
20. Fromigue O., Body J.J. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 2002, 25(6):539-546.
21. Xiong Y., Yang H.J., Feng J., Shi Z.L., Wu L.D. Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells. J Int Med Res 2009, 37(2):407-416.
22. Phadke P.A., Mercer R.R., Harms J.F., Jia Y., Frost A.R., Jewell J.L., et al. Kinetics of metastatic breast cancer cell trafficking in bone. Clin Cancer Res 2006, 12(5):1431-1440.
23. Kakonen S.M., Mundy G.R. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003, 97(3 Suppl.):834-839.
24. Brown H.K., Holen I. Anti-tumour effects of bisphosphonates-what have we learned from in vivo models?. Curr Cancer Drug Targets 2009, 9(7):807-823.
25. Holen I., Coleman R.E. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res 2010, 12(6):214.
26. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001, 296(2):235-242.
27. Roelofs A.J., Thompson K., Ebetino F.H., Rogers M.J., Coxon F.P. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 2010, 16(27):2950-2960.
28. van Beek E., Pieterman E., Cohen L., Lowik C., Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999, 264(1):108-111.
29. Weinstein R.S., Roberson P.K., Manolagas S.C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009, 360(1):53-62.
30. Hirbe A.C., Roelofs A.J., Floyd D.H., Deng H., Becker S.N., Lanigan L.G., et al. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 2009, 44(5):908-916.
31. Koch F.P., Merkel C., Al-Nawas B., Smeets R., Ziebart T., Walter C., et al. Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner-a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2. J Craniomaxillofac Surg 2011, 39(8):562-569.
32. Plotkin L.I., Weinstein R.S., Parfitt A.M., Roberson P.K., Manolagas S.C., Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999, 104(10):1363-1374.
33. Plotkin L.I., Bivi N., Bellido T. A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice. Bone 2011, 49(1):122-127.
34. Pozzi S., Vallet S., Mukherjee S., Cirstea D., Vaghela N., Santo L., et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res 2009, 15(18):5829-5839.
35. Brown H.K., Ottewell P.D., Evans C.A., Coleman R.E., Holen I. A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts. J Bone Oncol 2012, 1:47-56.
36. Mackie E.J., Tatarczuch L., Mirams M. The skeleton: a multi-functional complex organ: the growth plate chondrocyte and endochondral ossification. J Endocrinol 2011, 211(2):109-121.
37. Deckers M.M., Van Beek E.R., Van Der Pluijm G., Wetterwald A., Van Der Wee-Pals L., Cecchini M.G., et al. Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. J Bone Miner Res 2002, 17(6):998-1007.
38. Daubine F., Le Gall C., Gasser J., Green J., Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007, 99(4):322-330.
39. Aft R., Naughton M., Trinkaus K., Watson M., Ylagan L., Chavez-MacGregor M., et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010, 11(5):421-428.
40. Solomayer E.F., Gebauer G., Hirnle P., Janni W., Luck H.J., Becker S., et al. Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol 2012, 23(9):2271-2277.